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ABSTRACT Obstructive sleep apnoea (OSA) is a highly prevalent condition often associated with central
obesity. In the past few years, several studies have analysed the potential independent contribution of OSA
to the pathogenesis of metabolic abnormalities, including type 2 diabetes, the metabolic syndrome and non-
alcoholic fatty liver disease. New perspectives in OSA patient care have been opened by the promotion of
lifestyle interventions, such as diet and exercise programmes that could improve both OSA and the
metabolic profile. The rich clinical literature on this subject, together with the growing amount of data on
pathophysiological mechanisms provided by animal studies using the chronic intermittent hypoxia model,
urged the organising Committee of the Sleep and Breathing meeting to organise a session on sleep apnoea
and metabolic dysfunction, in collaboration with the European Association for the Study of Diabetes. This
review summarises the state-of-the-art lectures presented in the session, more specifically the relationship
between OSA and diabetes, the role of OSA in the metabolic consequences of obesity, and the effects of
lifestyle interventions on nocturnal respiratory disturbances and the metabolic profile in OSA patients.
@ERSpublications
Treatment of obesity and metabolic diseases through diet and exercise should be part of OSA
management besides CPAP http://ow.ly/mUd1R
Introduction
Obstructive sleep apnoea (OSA) is a highly prevalent condition often associated with central obesity. In the
past few years, the implications of the association of OSA and obesity have raised considerable interest, and
several studies have analysed the potential independent contribution of OSA to the pathogenesis of metabolic
abnormalities, including type 2 diabetes, the metabolic syndrome and non-alcoholic fatty liver disease. New
perspectives in OSA patient care have been opened by the promotion of lifestyle interventions, such as diet and
exercise programmes that could improve both OSA and the metabolic profile. The clinical consequence of
such approaches will be a better definition of therapeutic and preventive strategies in OSA patients.
The rich clinical literature on this subject, together with the growing amount of data on pathophysiological
mechanisms provided by animal studies using the chronic intermittent hypoxia model, urged the organising
Committee of the Sleep and Breathing meeting, held in Berlin in April 2013, and jointly organized by
European Respiratory Society and the European Sleep Research Society, to organise a session on sleep apnoea
and metabolic dysfunction, in collaboration with the European Association for the Study of Diabetes.
Received: May 16 2013 | Accepted after revision: June 19 2013
Conflict of interest: None declared.
Provenance: Submitted article, peer reviewed.
Copyright ERS 2013
REVIEW
SLEEP AND BREATHING
Eur Respir Rev 2013; 22: 353–364 | DOI: 10.1183/09059180.00003413 353
This review summarises the state-of-the-art lectures presented in the session, more specifically the relationship
between OSA and diabetes, the role of OSA in the metabolic consequences of obesity, and the effects of lifestyle
interventions on nocturnal respiratory disturbances and the metabolic profile in OSA patients.
OSA and type 2 diabetes: an independent relationship?
OSA and type 2 diabetes are two frequently associated conditions which share the same risk factors, i.e. male
sex, advancing age and obesity, particularly abdominal adiposity. The prevalence of type 2 diabetes in OSA
patients ranges from 15% to 30% depending on the study population, the definition of OSA severity and the
methods used to diagnose type 2 diabetes [1]. In the Wisconsin Sleep Study, the prevalence of type 2
diabetes increased according to the severity of OSA, and the odds ratio (OR) of having physician-diagnosed
type 2 diabetes was 2.30 (95% CI 1.28–4.11) when comparing those with an apnoea/hypopnoea index (AHI)
of o15 events?h-1 with those with an AHI of ,5 events?h-1. The OR was 3.48 (95% CI 1.69–7.18) when
comparing those with an AHI of .30 events?h-1 to controls after adjustment for age, sex and waist
circumference [2].
Similarly, the prevalence of OSA among patients with type 2 diabetes is high. In the Sleep Heart Health
Study [3], the prevalence of OSA (AHI o15 events?h-1) was 24.0% and 15.6% in patients with and without
type 2 diabetes, respectively. However, the difference in mean AHI between patients with versus without
type 2 diabetes was no longer significant after adjustment for age, sex, body mass index (BMI), ethnicity and
neck circumference. In the Sleep AHEAD study [4], the prevalence of OSA (AHI o15 events?h-1) was 53%
in overweight or obese patients with type 2 diabetes. Comparing such results to the estimated prevalence of
OSA in males and females of the same age range and BMI in the general population [5], the prevalence of
OSA among patients with type 2 diabetes [6–8] appears to exceed predictions of OSA in the general
population (fig. 1).
Considering the incidence of type 2 diabetes, the presence of OSA has been associated with an increased risk of
developing type 2 diabetes in some studies [8, 9] but not in others [2, 10] after adjustment for confounding
factors. Nevertheless, LINDBERG et al. [10] demonstrated that the deterioration of insulin sensitivity across an
11-year follow-up was associated with the severity of sleep breathing disorder at baseline.
In addition, several studies reported that sleep breathing disorders are associated with deterioration in
insulin sensitivity. For instance, PUNJABI and BEAMER [11] found a significant correlation between insulin
sensitivity measured by the frequently sampled intravenous glucose tolerance test and the severity of
nocturnal desaturations after adjustments for age, sex, ethnicity and per cent of body fat. PAMIDI et al. [12]
compared the insulin sensitivity (estimated from 75-g oral glucose tolerance test) of healthy young males
with or without OSA matched for family and ethnic risks of developing type 2 diabetes. Males having OSA
showed lower insulin sensitivity compared to males without OSA. It was recently found that insulin
resistance in OSA patients was independently associated with the severity of nocturnal desaturations, but
not with abdominal adiposity, in non-obese patients (unpublished data).
If insulin resistance is clearly associated with sleep breathing disorders, mechanistic explanations require
further research (fig. 2). Intermittent hypoxia and sleep fragmentation associated with OSA are known to
induce sympathetic activation, low-grade inflammation, activation of hypothamic-pituitary-adrenal axis
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FIGURE 1 Prevalence of obstructive sleep apnoea (OSA) (apnoea/hypopnoea index o15 events?h-1) in a) males aged 50–69 years and b) females aged 50–69 years
with type 2 diabetes compared with estimated prevalence (—) in a general population of the same age range and body mass index (BMI). DT2: type 2 diabetes;
SHHS: Sleep Heart Health Study.
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and increased oxidative stress [13]. Such intermittent hypoxia-related intermediate mechanisms are known
to alter insulin signalling, as was directly demonstrated by some cultured cell and murine studies [14, 15].
Several studies, already published or ongoing, have addressed the question of the effects of continuous
positive pressure (CPAP) treatment on glucose metabolism and glycaemic control in patients with type 2
diabetes. WEST et al. [16] conducted a 3-month CPAP versus sham-CPAP randomised study in patients with
type 2 diabetes; this study did not show any benefit of CPAP treatment on HbA1c or insulin sensitivity.
WEINSTOCK et al. [17] measured insulin sensitivity estimated from oral glucose tolerance test in patients with
glucose intolerance before and after 2 months of CPAP treatment in a cross-over design with control
treatment by sham-CPAP. CPAP treatment did not reverse glucose intolerance or improve insulin
sensitivity, except in patients with severe OSA (AHI .30 events?h-1). Finally SHARMA et al. [18] conducted a
cross-over study with 3 months of CPAP compared to 3 months of sham-CPAP treatment in patients with
OSA (AHI o15 events?h-1) and daily sleepiness; patients with type 2 diabetes, hypertension or
dyslipidaemia were excluded. In this study, 3 months of CPAP treatment reduced HbA1c levels, as well
as body weight and visceral fat accumulation. Thus, in this positive study, it is unclear whether the
metabolic improvements were linked to CPAP treatment or to the reduction in fat accumulation that was
associated with it. Furthermore, HOYOS et al. [19] have addressed the question of the potential benefit of
CPAP treatment on visceral and liver fat accumulation in a 3-month controlled study and did not find any
reduction in visceral or liver fat accumulation, while CPAP treatment was associated with an increase in fat-
free mass.
In conclusion, while some differing results remain, prevalence of type 2 diabetes in patients with OSA seems
more frequent than in patients without OSA after controlling for confounding factors. However, OSA
prevalence among patients with type 2 diabetes seems to exceed prevalence in the general population for the
same age range and BMI. OSA might increase the risk of developing type 2 diabetes through deterioration in
insulin sensitivity. Whether CPAP therapy is able to improve glycaemic control or insulin sensitivity or
prevent incident cases of type 2 diabetes, is not clearly established yet. Results of ongoing studies as well as
further studies will probably provide answer to these questions.
The role of OSA in the metabolic consequences of obesity
In recent years, the potential role of OSA in the pathogenesis of metabolic abnormalities has been extensively
investigated both in patients and animal models. As summarised in a recent review [20], visceral obesity and
OSA share some mechanisms, with a potential synergistic effects when the two conditions are combined.
Adipose tissue in obesity shows increased macrophage infiltration with predominance of cells with a pro-
inflammatory pattern of activation [21]. In addition, two groups of investigators recently reported that large
adipocytes were hypoxic in obese mice [22, 23]. An increased distance between adipocytes and capillaries and
insufficient capillary growth were proposed as possible mechanisms responsible for these findings [24].
Intermittent hypoxia/sleep fragmentation
Deterioration of insulin signalling
HPA stimulation Oxidative stress Low grade
inflammation
Sympathetic
activation
Insulin sensitivity
FIGURE 2 Intermediary mechanisms implicated in the deterioration of insulin sensitivity in obstructive sleep apnoea
patients. HPA: hypothamic-pituitary-adrenal.
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Adipocyte hypoxia in obese animals was associated with activation of both inflammatory and hypoxia-inducible
factor (HIF)-1 dependent pathways and evidence of endoplasmic reticulum stress [22, 23]. Two studies
analysing subcutaneous adipose tissue from obese humans reported similar findings, i.e. lower tissue oxygen
tension (PO2) in adipose tissue of obese subjects associated with reduced circulating vascular endothelial growth
factor (VEGF) levels and number of capillaries in fat [25, 26].
These findings raised interest on the potential role of hypoxia in the pathogenesis of metabolic abnormalities
in OSA, but the effects of intermittent hypoxia in adipose tissue were unknown. REINKE et al. [27] measured
tissue PO2 in different organs during intermittent hypoxia, and reported that visceral adipose tissue showed
much smaller PO2 oscillations compared to liver or muscle. Interestingly, no major differences were noted
between lean and obese animals. Blunted PO2 oscillations in visceral adipose tissue during acute intermittent
hypoxia or obstructive apnoeas were also reported by ALMENDROS et al. [28] in a lean rat model. In summary,
experimental results do not suggest a major effect of intermittent hypoxia or obstructive apnoeas on the level
of visceral adipose tissue oxygenation.
More recently, two different studies in the obesity literature have questioned that adipose tissue is hypoxic
in obese humans. GOOSSENS et al. [29] showed that abdominal subcutaneous adipose tissue PO2 is higher in
obese compared to lean subjects, while HODSON et al. [30] demonstrated that the metabolic rate of
subcutaneous adipose tissue is significantly lower in obese compared to lean humans. These findings may be
accounted for by decreased adipose tissue metabolism in obesity: low oxygen requirement can be expected
to be associated with increased tissue PO2, low VEGF levels and decreased capillary growth [31]. The
differences between results obtained in rodents and humans could be explained by the rapid rate of onset of
obesity in animal models compared to the slow development of human obesity; in addition, rodent models
develop a very high degree of obesity compared to humans [32]. The debate is still ongoing and additional
studies in vitro and in vivo will be necessary, given the extreme complexity of the pathophysiology of human
obesity. However, new experiments should be carefully designed in order to mimic physiological PO2 levels
in adipose tissue. Conversely, available data were mainly obtained by exposing adipose tissue cells in vitro to
extremely high or low values of PO2 [32]. Other uncertain areas relate to the potentially different effects of
intermittent hypoxia on subcutaneous fat, visceral fat and brown adipose tissue (BAT). Available data have
been mainly collected in subcutaneous fat in humans, and in visceral fat in rodent models. In morbidly
obese patients undergoing bariatric surgery, ARON-WISNEWSKY et al. [33] found no association between
intermittent hypoxia and macrophage accumulation or adipocyte size in omental or subcutaneous fat; tissue
PO2 was not measured. As BAT is concerned, a trend towards decreased body weight and BAT in rats
exposed to isocapnic intermittent hypoxia for 3 weeks has been reported [34]. No study to date has
examined the role of chronic intermittent hypoxia on the transition from white to brown adipocytes, a topic
of great interest in the current obesity literature.
OSA, visceral fat and the metabolic syndrome
The close relationship between visceral fat accumulation and OSA has been known for a long time. In 2000,
VGONTZAS et al. [35] reported that the main difference between obese patients with and without OSA was
the amount of abdominal visceral fat deposition, which was higher in OSA patients than in obese controls
while the amount of subcutaneous fat was similar in both groups. Moreover, the amount of visceral fat, but
not BMI or the amount of subcutaneous fat, showed a high degree of correlation with measures of OSA
severity, such as the AHI or nocturnal intermittent hypoxemia [35].
Visceral fat accumulation is the main feature of the metabolic syndrome (MetS). Not surprisingly, MetS is
highly prevalent in OSA patients, with variable rates between 50% and .80% reported in studies worldwide
(fig. 3). MetS is diagnosed in clinical practice by the NCEP-ATP (National Cholesterol Education Programme-
Adult Treatment Panel) III criteria, which require the presence of three out of five criteria [36–45]. The
number of MetS criteria is defined as the metabolic index and can be used as an indicator of severity of
metabolic abnormalities. Patients with severe OSA showed a significantly higher metabolic index compared to
patients with mild-to-moderate OSA [45], and this finding has been also confirmed in patients primarily
identified for the presence of MetS [46] or morbid obesity [47]. An independent role of OSA on metabolic
abnormalities is not strongly supported by randomised controlled trials rigorously testing the effect of CPAP
on metabolism in OSA patients. A recent meta-analysis examining five controlled studies in non-diabetic OSA
patients reported a significant, but quite small, effect of CPAP on metabolism [48]. These results need further
confirmation by larger randomised studies.
Sex may exert a major role in the relationship between obesity and OSA. Sex differences in clinical
presentation of OSA have been highlighted since the first studies on OSA, showing that OSA is less severe in
females than in males with a comparable degree of obesity [49, 50]. A recent case–control study examined
adipose tissue distribution in overweight males and females with and without OSA matched for age and
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body weight [51]. The study confirmed the known relationship between computed tomography-assessed
visceral fat and OSA, and an increased visceral-to-subcutaneous fat ratio in males with OSA. However, in
females visceral fat or the visceral-to-subcutaneous fat ratio did not differ between overweight females with
or without OSA, suggesting that OSA in the female sex might be related to total adiposity more than to
visceral adiposity [51].
Increased neck circumference is another marker of visceral adiposity frequently associated with OSA.
Several studies have recently assessed its independent contribution to prediction of OSA severity, with
variable results. What is missing in the current literature is the analysis of markers of obesity and metabolic
abnormalities while taking sex into account. Such analysis could provide a better definition of the
phenotype of OSA in obese subjects in relation to cardiovascular risk according to sex. It is possible that
phenotypes with different risk profiles might occur in OSA patients, with obvious consequences regarding
the need for individualised treatment. However, increased cardiovascular morbidity and mortality have
been found in longitudinal studies in females with severe OSA [52], suggesting that the impact of OSA is
similar in both sexes.
OSA and liver damage
The liver is an important target in patients with MetS, and liver steatosis is a major manifestation of insulin
resistance [20]. Some studies have suggested that OSA may worsen liver dysfunction in obese patients by
promoting the shift from simple steatosis to non-alcoholic steatohepatitis (NASH). Chronic intermittent
hypoxia exposure would be the most important pathogenetic mechanism leading to NASH, as shown by
studies in animal models [53]. To date, at least two studies have assessed liver morphology in humans in
relation to OSA severity [33, 54]; both analysed liver biopsies obtained in morbidly obese patients
undergoing bariatric surgery and reported a strong association between severity of nocturnal intermittent
hypoxia and liver abnormalities (steatosis and fibrosis).
Other studies have examined the association of non-alcoholic fatty liver disease and OSA with differing
results, possibly explained by different features of the studied patients and methodology used to assess liver
abnormalities [20]. At present, little data are available on liver morphology and function in non-morbidly
obese OSA patients before and after CPAP treatment. It is possible that ‘‘usual’’ OSA patients may show
different features compared to patients undergoing bariatric surgery. In addition, the latter patients are
predominantly females and sex distribution is different from that commonly observed in clinical OSA series.
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FIGURE 3 Prevalence rates of Metabolic Syndrome (MetS) in obstructive sleep apnoea syndrome (OSAS) patients
worldwide.
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Lifestyle interventions: metabolic benefits of exercise and weight reduction in OSA
Lifestyle interventions generally encompass the key domains of diet and exercise and are driven by the
vehicle of overall ‘‘behavioural change’’. While there is a clear benefit of weight loss amongst the generally
obese population, less data is available regarding weight loss for the patient with OSA. This extends to a lack
of information regarding the specific dietary and/or exercise prescription and the intensity of the weight loss
recommended for patients with OSA [55].
Obesity is the most important major modifiable risk factor associated with OSA [56]. A weight gain of 10%
is associated with a 32% increase in disease severity (AHI) while a 10% weight loss resulted in a disease
severity reduction of 26% [57]. OSA is an independent risk factor for the development of cardiovascular
disease, hypertension and type 2 diabetes [42, 58–63]. OSA, obesity and MetS are a common disease cluster
that often present to pulmonary and sleep clinicians as a mutually confounding health risk.
Visceral or central adipose tissue is thought to be the source of many of the metabolic abnormalities that
contribute to the increased cardiovascular risk associated with obesity. Hence, the emphasis of lifestyle
modification should be on the reduction of central fat (i.e. waist circumference) for obese individuals. There
is clear evidence that 5–10% of weight loss in an obese patient translates into a marked reduction in blood
pressure, lipid profile and improved insulin sensitivity, as well as improvement in other thrombotic factors
and inflammatory markers for an overall reduction in the risk of coronary heart disease [64]. Although
CPAP is considered the gold standard treatment for severe OSA, it variably ameliorates OSA related
symptoms and hypertension, and it is unclear whether it impacts on insulin sensitivity [65–67].
Expert panels recommend lifestyle modification interventions in OSA by promoting physical activity and
weight loss [68, 69]. Weight loss is an important treatment option, especially in the non-sleepy patient who
requires simultaneous OSA and metabolic risk management. Sleep-disordered breathing may impede the
improvement of cardiometabolic risk profile in response to a 1-year lifestyle modification programme [70].
Following intervention, males with OSA and visceral obesity demonstrated significantly smaller reductions
in BMI, waist circumference, fat mass and triglycerides and significantly smaller increases in adiponectin
and high-density lipoprotein cholesterol compared to males with visceral obesity and no OSA [70].
However, more studies, including randomised trials, are required to determine whether this resistance to
weight loss needs to be considered in the lifestyle prescription for the patient with OSA.
A recent systematic review and meta-analysis assessed randomised controlled trials in the area of lifestyle
interventions in OSA [55]. Conservative weight loss approaches included an assortment of cognitive
behavioural therapy and dietary prescription, sleep hygiene, home diets and self-managed exercise. Three
randomised trials have investigated the effect of dietary weight loss versus dietary weight loss plus CPAP
[71–73] and the meta-analysis observed a significant reduction in weight for those patients receiving diet
plus CPAP intervention compared with the control group (table 1). The lifestyle interventions varied and
did not consistently prescribe exercise or provide specific dietary recommendations or lifestyle counselling.
The heterogeneity in the dietary recommendations and weight loss programmes makes it difficult to
conclude that the information can be pooled and compared, and is therefore limited in generalisability.
Intensive lifestyle interventions have a variety of features including very low energy diets, supervised exercise
programmes and tailored dietary prescriptions. Six randomised controlled trials have compared the effect of
intensive lifestyle changes versus routine care in OSA [74–79]. The trials were mixed in duration, design and
protocols employed, and no consistency was observed in the diet, exercise or structuring of the programmes
employed (table 1). Overall, it is clear that intensive lifestyle interventions employing a caloric restriction and/or
physical activity are effective for reducing obesity and improve the severity of OSA. Lower intensity interventions
combined with CPAP therapy also work, however to a lesser degree for the same outcome measures.
Despite weight loss being important for the overall health management of patients with OSA who are
overweight or obese, there are little data regarding the most effective diet for OSA patients. Very low energy
diets have been widely used according to a variety of protocols; however, there are only two diets that have
been tested against each other specifically in OSA patients, the Mediterranean diet versus the prudent diet
[77]. The AHI during rapid eye movement sleep was reduced in the Mediterranean diet group compared to
the prudent diet. Waist circumference and waist-to-hip ratio were also reduced to a greater extent in the
Mediterranean diet group when compared with the prudent diet group. This supports recent evidence from
a randomised trial that the Mediterranean diet supplemented with extra-virgin olive oil reduces the
incidence of major cardiovascular events among persons at high cardiovascular risk [83]. Furthermore, a
recent systematic review and meta-analysis revealed that the Mediterranean diet had the most pronounced
effect on glycaemic control and greater weight loss in the management of type 2 diabetes [84]. There is a
clear need for broader investigation comparing effectiveness of a variety of dietary protocols and
macronutrient compositions in the obese OSA patient.
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Exercise is an essential component of lifestyle modification for the management of OSA, but studies
specifically evaluating the efficacy of exercise training in OSA are limited by the relatively small sample sizes
and the frequent lack of control groups [80, 85–88]. The methodological differences complicate any form of
meaningful comparison in the exercise prescribed. The fact that obesity is so strongly linked to OSA
suggests that exercise prescriptions should be designed on the basis of weight loss.
The American College of Sports Medicine (ACSM) currently recommends .250 minutes per week of
moderate intensity cardiorespiratory exercise for clinically significant weight loss in addition to two strength
training sessions [89]. The typical characteristics of the OSA patient, being sleepy and lacking energy, may
compromise an individual’s ability to sustainably comply with high volumes of exercise. Therefore, tailored
exercise programmes fostering progressive overload and gradual conditioning of the individual may require
consideration. Recent evidence suggests that exercise training may be associated with a reduction in OSA
severity [78, 87, 88, 90] and, not surprisingly, improved exercise capacity [84, 85, 87, 91]. Exercise alone
may also improve OSA severity without significant weight loss [77, 88, 90]. More specifically, KLINE et al.
[91] tested the effects of aerobic exercise for 4 days per week in a supervised environment at moderate
intensity (equating to 150 minutes per week) combined with resistance training. The exercise dose did not
reach the volume recommended by the ACSM for clinically significant weight loss [89]. The exercise dose
prescribed is often based on recommendations for diabetics, despite the volume not being adequate for
weight loss without dietary intervention. Nevertheless, KLINE et al. [91] found significant improvement in
depressive symptoms, fatigue and vigour aspects of quality of life. A significant 25% reduction in AHI
(p,0.01) and oxygen desaturation index (p50.03) was observed for the exercise group, while the decrease
in body weight did not reach significance [91].
While CPAP usually ameliorates OSA symptoms of sleepiness and improves quality of life [71], it must be
used in adjunct with intensive lifestyle interventions incorporating the use of very low energy diets to
achieve aggressive weight reduction, followed by more sustainable eating plans and frequent exercise. A
minimum of 150 minutes per week of aerobic exercise should be recommended in addition to at least two
sessions of strength training to promote lean muscle gain [89]. In this way, weight re-gain can be prevented.
There is a clear gap in the knowledge regarding the most effective diet to recommend to patients with OSA
and furthermore, what volume of exercise will most benefit OSA and weight loss.
One of the problems impacting on delivery of the best healthcare to OSA patients is fragmentation of
services and treatments. Mechanical therapies are implemented by sleep or dental specialists, while lifestyle
modification is usually managed by other teams. The way forward is to integrate both clinical training and
management, to ensure interdisciplinary skills in the full range of OSA therapeutics in one setting. It will be
important to underpin this disruption of therapeutic silos by more randomised controlled trials built from
the current knowledge base, to further unveil the role of lifestyle modification and exercise in the
management of OSA [92, 93]. While there is a clear benefit in employing intensive lifestyle interventions
with or without CPAP therapy for the management of the obese OSA patient, further exploration into the
most effective lifestyle prescription (encompassed by a specific diet and exercise programme) is warranted.
The relative effectiveness of weight loss versus CPAP or mandibular advancement devices from a metabolic
perspective is yet to be confirmed, as does a comparison of weight loss in males versus females and in
comorbid type 2 diabetes. Furthermore, the feasibility and sustainability of delivering these programmes in
a clinical environment must be explored. Chronic care models managing obesity, such a lifestyle
modification targeting ‘‘waist loss’’ [64], demand further validation as does a parallel change in health
promotion and the social constructs around managing obesity and OSA. It is essential for OSA and obesity
chronic care to be combined, whereby there is an up skilling of both the sleep medicine and obese/metabolic
medical workforce. This also necessitates the investigation of adherence issues common with CPAP use and
long-term weight loss therapeutic commitment and sustainability.
Conclusions
New perspectives have opened up for the management of OSA patients due to the most recent studies on
insulin resistance and diabetes in OSA and obesity, especially because such new pieces of knowledge will
impact on prevention and treatment of metabolic problems. The new insight into adipose tissue biology
may provide useful information to understand the real impact of OSA on adipocyte function and to design
new treatment options to improve control of body weight. Finally, OSA treatment based on CPAP should
be extended to include carefully targeted lifestyle interventions, since the available data confirm the positive
role of diet and exercise in OSA patients, although specifically designed interventions for these patients are
still lacking. Hopefully, a modern integrated approach for OSA and obesity could improve the results of
OSA treatment and help decrease the high cardiovascular risk profile typical of these patients.
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